Progress of Burkitt lymphoma treatment

VernacularTitle: 伯基特淋巴瘤治疗研究进展
Author: Hongtao REN ¹ ; Huizheng BAO ; Hao YU ; Na XU ; Na LI ; Hong XIA ; Chengyi JIANG ; Lu LIU
Author Information

1. Department of Lymphoma and Hematology, Jilin Cancer Hospital, Changchun 130000, China
Publication Type:Review
Keywords: Burkitt lymphoma; Treatment; Adverse reactions; New drugs
From: Journal of Leukemia & Lymphoma 2018;27(4):206-208
CountryChina
Language:Chinese
Abstract: Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma which often occurs in children. The cure rate of BL is significantly increased with the wide application of short-duration and high-intensity immunochemotherapy, however, chemotherapy-related adverse reactions are still a big problem in adult patients and human immunodeficiency virus (HIV) positive patients. Meanwhile, the absence of effective immune targeting new drugs in patients with relapsed and refractory BL needs to be solved clinically. How to optimize the therapeutic regimen to reduce the chemotherapy-related adverse reactions and develop effective immune targeting new drugs is the hot spot in current research. This paper reviews the treatment progress of BL according to the 59th American Society of Hematology (ASH) Annual Meeting.